Elevar Therapeutics, Inc.
https://elevartherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Elevar Therapeutics, Inc.
2023 Review: Chinese-Sponsored Phase III US Trials See Uptick
Companies from China single-handedly sponsored a total of eight Phase III clinical studies that included US sites in 2023 compared to six in 2022 - but the figure was still below the record of 11 in 2021.
10 Years On, Chinese Biopharma Firms Making US Inroads: A Snapshot
From 2013 to November 2022, Chinese pharma companies as a single sponsor started a total of 35 international Phase III clinical studies for innovative drugs in the US, indicating a continuing push by the biopharma sector in the country to leverage increasing innovation to access this huge and lucrative market. Led by BeiGene, 20 firms have placed their bets on such studies and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.
10 Years On, Chinese Biopharma Firms Making Inroads In US Clinical Trials
Led by BeiGene, 20 firms have placed their bets on Phase III clinical studies for innovative drugs in the US and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.
10 Years On, Chinese Biopharma Firms Making US Inroads: A Snapshot
From 2013 to November 2022, Chinese pharma companies as a single sponsor started a total of 35 international Phase III clinical studies for innovative drugs in the US, indicating a continuing push by the biopharma sector in the country to leverage increasing innovation to access this huge and lucrative market. Led by BeiGene, 20 firms have placed their bets on such studies and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- LSKB
- LSK BioPharma
- LSK BioPartners, Inc.
- LSKB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice